Abstract:BACKGROUND Pancreatic cancer is a leading cause of cancer-related deaths. Increased activity of the epidermal growth factor receptor (EGFR) is often observed in pancreatic cancer, and the small molecule EGFR inhibitor erlotinib has been approved for pancreatic cancer therapy by the food and drug administration. Nevertheless, erlotinib alone is ineffective and should be combined with other drugs to improve therapeutic outcomes. We previously showed that certain receptor tyrosine kinase inhibitors can increase mitochondrial membrane potential (Δψm), facilitate tumor cell uptake of Δψm-sensitive agents, disrupt mitochondrial homeostasis, and subsequently trigger tumor cell death. Erlotinib has not been tested for this effect. AIM To determine whether erlotinib can elevate Δψm and increase tumor cell uptake of Δψm-sensitive agents, subsequently triggering tumor cell death. METHODS Δψm-sensitive fluorescent dye was used to determine how erlotinib affects Δψm in pancreatic adenocarcinoma (PDAC) cell lines. The viability of conventional and patient-derived primary PDAC cell lines in 2D- and 3D cultures was measured after treating cells sequentially with erlotinib and mitochondria-targeted ubiquinone (MitoQ), a Δψm-sensitive MitoQ. The synergy between erlotinib and MitoQ was then analyzed using SynergyFinder 2.0. The preclinical efficacy of the two-drug combination was determined using immune-compromised nude mice bearing PDAC cell line xenografts. RESULTS Erlotinib elevated Δψm in PDAC cells, facilitating tumor cell uptake and mitochondrial enrichment of Δψm-sensitive agents. MitoQ triggered caspase-dependent apoptosis in PDAC cells in culture if used at high doses, while erlotinib pretreatment potentiated low doses of MitoQ. SynergyFinder suggested that these drugs synergistically induced tumor cell lethality. Consistent with in vitro data, erlotinib and MitoQ combination suppressed human PDAC cell line xenografts in mice more effectively than single treatments of each agent. CONCLUSION Our findings suggest that a combination of erlotinib and MitoQ has the potential to suppress pancreatic tumor cell viability effectively.

Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells

Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells.

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Inhibition of Mitochondrial Redox Signaling with MitoQ Prevents Metastasis of Human Pancreatic Cancer in Mice

Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents

Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment

Mitochondria targeted metabolic inhibitors promote lymphocyte infiltration into murine pancreatic tumors

mCAUSE: Prioritizing mitochondrial targets that alleviate pancreatic cancer cell phenotypes

Peptide Nucleic Acids Targeting Mitochondria Enhances Sensitivity of Lung Cancer Cells to Chemotherapy

Biological Evaluation of Mitochondria Targeting Small Molecules As Potent Anticancer Drugs.

Pleiotropic Effects of a Mitochondrion-Targeted Glutathione Reductase Inhibitor on Restraining Tumor Cells.

Targeting Mitochondrial Dysfunctions in Pancreatic Cancer Evokes New Therapeutic Opportunities

Progress in the Study of Anti-Tumor Drugs Targeting Mitochondria

Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription.

Novel Prodrug Supramolecular Nanoparticles Capable of Rapid Mitochondrial-Targeted and ROS-Responsive for Pancreatic Cancer Therapy

Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival

Mitochondria targeted cancer therapy using ethidium derivatives

Novel prodrug supramolecular nanoparticles capable of rapid mitochondrial-targeting and ROS-responsiveness for pancreatic cancer therapy

Discovery And Characterization Of Dual Inhibitors Of Mdm2 And Nfat1 For Pancreatic Cancer Therapy

Abstract 4779: MnSOD mimetic mitoquinone mesylate (MitoQ) increases DCLK1+pancreatic cancer stem cells

An inhibitor of oxidative phosphorylation exploits cancer vulnerability